DelveInsight’s “Dry Eye Disease Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Dry Eye Disease market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Dry Eye Disease drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Dry Eye Disease treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Dry Eye Disease: An Overview
Dry eye disease (DED), also known as dry eye syndrome (DES) or keratoconjunctivitis sicca (KCS), is a common condition when the eyes do not produce enough tears or the tears evaporate too quickly. As tears are essential to lubricate and nourish the eye, the condition leads to eyes drying out and becoming red, swollen, and irritated. Causes for Dry Eye Disease include decreased tear production, excessive tear evaporation, and abnormality in the production of mucus or lipids of the tear layer.
It is caused by a chronic lack of sufficient lubrication and moisture on the surface of the eye. Consequences of dry eyes range from subtle but constant eye irritation to significant inflammation and even scarring of the front surface of the eye. It can affect one or both eyes, and it can lead to inflammation.
The main symptom of dry eye is a dry and gritty feeling in the eyes. The additional symptoms include burning or itching in the eyes, foreign body sensation, excess tearing, pain and redness of the eyes, and photophobia in some cases. Sometimes, it is also associated with a stringy discharge and blurred, changing vision. Besides, the symptoms are found to worsen in dry weather, with low humidity, and higher temperatures. Having dry eyes for a while can lead to tiny abrasions on the surface of the eyes. In advanced cases, the epithelium undergoes pathologic changes, namely squamous metaplasia and loss of goblet cells.
Dry Eye Disease Market Key Facts
-
According to Dana et al. (2019), the overall Dry Eye Disease prevalence was 5.28%, wherein the prevalence among females and males was about 7.78% and 2.96%, respectively, in the US. Besides, the prevalence increased with age from 0.20%, for ages 2–17 years, to 11.66% for individuals aged above 50.
-
According to a study by Dalton et al. (2019), around 16 million Americans have been diagnosed with Dry Eye Disease, but the actual number of Americans suffering from dry eye symptoms is likely much higher. Some reports indicate that nearly half of all US adults experience dry eye signs and symptoms, and 33% of patients in eye care clinics present with complaints about dry eye.
-
According to the Association of Optometrists, dry eye is a very common condition in the UK, affecting one in four people in the UK.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Dry Eye Disease pipeline therapies. It also thoroughly assesses the Dry Eye Disease market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete details of the market trend for each marketed Dry Eye Disease drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Dry Eye Disease Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Dry Eye Disease epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Dry Eye Disease epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Dry Eye Disease Epidemiology, Segmented as –
-
Total Prevalent Cases of Dry Eye Disease in the 7MM [2019–2032]
-
Total Diagnosed Prevalent Cases of Dry Eye Disease in the 7MM [2019–2032]
-
Type-specific Diagnosed Prevalent Cases of Dry Eye Disease in the 7MM [2019–2032]
-
Severity-specific Diagnosed Prevalent Cases of Dry Eye Disease in the 7MM [2019–2032]
-
Age-specific Diagnosed Prevalent Cases of Dry Eye Disease in the 7MM [2019–2032]
-
Gender-specific Diagnosed Prevalent Cases of Dry Eye Disease in the 7MM [2019–2032]
-
Treated Cases of Dry Eye Disease in the 7MM [2019–2032]
Dry Eye Disease Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Dry Eye Disease market or expected to be launched during the study period. The analysis covers the Dry Eye Disease market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Dry Eye Disease drugs based on their sale and market share.
The report also covers the Dry Eye Disease pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Dry Eye Disease companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Dry Eye Disease Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/dry-eye-disease-market-insights
Dry Eye Disease Therapeutics Analysis
The disease management aims to relieve the discomfort and prevent damage to the cornea, at the front of the eye. Currently, the available treatment options for Dry Eye Disease depend on the severity of the condition. They may include medication, surgery, and others (eyelid therapy [warm compresses and eyelid hygiene, contact lenses, and moisture chamber spectacles]).
Treatment depends on the underlying cause. Artificial tears are the usual first-line treatment. Wrap-around glasses that fit close to the face may decrease tear evaporation. Stopping or changing certain medications may help. The medication cyclosporine or steroid eye drops may be used in some cases. Another option is lacrimal plugs that prevent tears from draining from the surface of the eye. DES occasionally makes wearing contact lenses impossible. Various therapies like MIEBO (perfluorohexyloctane ophthalmic solution), XIIDRA (lifitegrast ophthalmic solution), and TYRVAYA nasal spray, among others are approved for the treatment of the signs and symptoms of dry eye disease
The dynamics of the Dry Eye Disease market are anticipated to experience a positive shift in the coming years owing to the expected launch of a barrage of emerging therapies like OTX-DED (Ocular Therapeutix), HL036 (tanfanercept) (HanAll Biopharma/Daewoong Pharmaceutical, PL9643 (Palatin Technologies) and many others in the upcoming years.
Dry Eye Disease Companies Actively Working in the Therapeutics Market Include
Some of the key companies in the Dry Eye Disease Market include Alcon, Allysta Pharmaceuticals, Aramis Biosciences, BRIM Biotechnology, Dreamhawk Vision Biotech, Inc., HanAll Biopharma, Invirsa, IVIEW Therapeutics, Kowa Company, MC2 Therapeutics, Novaliq, Novaliq GmbH, Noveome, Ocular Therapeutix, Palatin Technologies, Quorum Innovations, Seikagaku Corporation, Seinda Pharmaceutical, Serentrix, Taejoon Pharmaceutical, and others.
Emerging and Marketed Dry Eye Disease Therapies Covered in the Report Include:
-
A197: Aramis Biosciences
-
AR-15512: Aerie Pharmaceuticals
-
CLX-OPH-621: Cellix Bio
-
CyclASol: Novaliq GmbH
-
GLH8NDE: GL Pharm TechCorporation
-
HL036: HanAll Biopharma
-
INV-102: Invirsa
-
iVIEW 1001: IVIEW Therapeutics
-
K-161: Kowa Research Institute, Inc.
-
NOV03: Novaliq GmbH
-
OTX-DED: Ocular Therapeutix
-
Qi 401: Quorum Innovations
-
SER-114: Serentrix
-
SHJ 002: Dreamhawk Vision Biotech, Inc.
-
SI-614: Seikagaku Corporation
-
SY-201: Seinda Pharmaceutical
-
TJO-083: Taejoon Pharmaceutical Co., Ltd.
And Many More
Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @
https://www.delveinsight.com/sample-request/dry-eye-disease-market-insights
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Dry Eye Disease Competitive Intelligence Analysis
4. Dry Eye Disease Market Overview at a Glance
5. Dry Eye Disease Disease Background and Overview
6. Dry Eye Disease Patient Journey
7. Dry Eye Disease Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Dry Eye Disease Treatment Algorithm, Current Treatment, and Medical Practices
9. Dry Eye Disease Unmet Needs
10. Key Endpoints of Dry Eye Disease Treatment
11. Dry Eye Disease Marketed Therapies
12. Dry Eye Disease Emerging Drugs and Latest Therapeutic Advances
13. Dry Eye Disease Seven Major Market Analysis
14. Attribute Analysis
15. Dry Eye Disease Market Outlook (In US, EU5, and Japan)
16. Dry Eye Disease Companies Active in the Market
17. Dry Eye Disease Access and Reimbursement Overview
18. KOL Views on the Dry Eye Disease Market
19. Dry Eye Disease Market Drivers
20. Dry Eye Disease Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Request the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/dry-eye-disease-market-insights
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
“Galactosemia Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Galactosemia market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Galactosemia market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/market-research